loading

Pasithea Therapeutics Corp Aktie (KTTA) Neueste Nachrichten

pulisher
May 20, 2025

Pasithea’s PAS-004 shows promise in inflammatory disease study - Investing.com Australia

May 20, 2025
pulisher
May 20, 2025

Pasithea Therapeutics Announces Preclinical Data That Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases - marketscreener.com

May 20, 2025
pulisher
May 20, 2025

Pasithea Therapeutics Reports Promising Preclinical Data for PAS-004 as a Novel MEK Inhibitor for Inflammatory Diseases - Nasdaq

May 20, 2025
pulisher
May 20, 2025

Pasithea Therapeutics Announces Preclinical Data that Shows - GlobeNewswire

May 20, 2025
pulisher
May 20, 2025

Breakthrough: Novel IBD Drug Outperforms FDA-Approved Treatment in Targeting Key Inflammation Pathway - Stock Titan

May 20, 2025
pulisher
May 15, 2025

Neurofibromatosis Type 1 Market Set to Witness Significant Growth During the Study Period (2020–2034) Driven by Advances in Treatment | DelveInsight - GlobeNewswire Inc.

May 15, 2025
pulisher
May 15, 2025

Pasithea to commence Phase I/Ib trial of neurofibromatosis type 1 therapy - Yahoo Finance

May 15, 2025
pulisher
May 14, 2025

Pasithea Therapeutics CEO sells shares worth $792 - Investing.com

May 14, 2025
pulisher
May 14, 2025

Pasithea Therapeutics Announces Initiation Of Phase 1/1B Study Of Pas-004 In Adult Nf1 Patients And Activation Of First Clinical Trial Site - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

Pasithea Therapeutics Announces Initiation of Phase 1/1B - GlobeNewswire

May 14, 2025
pulisher
May 14, 2025

Phase 1/1b Trial: Pasithea's Once-Daily NF1 Drug Could Outperform Current Treatments - Stock Titan

May 14, 2025
pulisher
May 07, 2025

Pasithea Therapeutics Raises $6.3 Million in Stock Offering - TipRanks

May 07, 2025
pulisher
May 07, 2025

Pasithea Therapeutics Closes $5 Million Public Offering to Advance Development of PAS-004 for Neurofibromatosis and Cancer Indications - Nasdaq

May 07, 2025
pulisher
May 07, 2025

Pasithea Therapeutics Announces Closing of $5 Million Public Offering - GlobeNewswire

May 07, 2025
pulisher
May 07, 2025

Pasithea Therapeutics 3.57M share Secondary priced at $1.40 - Yahoo Finance

May 07, 2025
pulisher
May 06, 2025

Pasithea Therapeutics Stock Soars After Positive Data From Cancer Drug Trial: Retail’s Elated - Asianet Newsable

May 06, 2025
pulisher
May 06, 2025

Pasithea Therapeutics Announces Pricing Of $5 Million Public Offering - marketscreener.com

May 06, 2025
pulisher
May 06, 2025

Pasithea Therapeutics Stock Soars After Positive Data From Cancer Drug Trial: Retail’s Elated By Stocktwits - Investing.com India

May 06, 2025
pulisher
May 06, 2025

Pasithea Therapeutics Prices $5 Million Public Offering - marketscreener.com

May 06, 2025
pulisher
May 06, 2025

Pasithea Therapeutics announces interim data from Phase 1 trial of PAS-004 - TipRanks

May 06, 2025
pulisher
May 06, 2025

Pasithea Therapeutics Announces Pricing of $5 Million Public Offering - The Manila Times

May 06, 2025
pulisher
May 06, 2025

Pasithea Therapeutics (KTTA) Skyrockets: Stock Soars Over 115% in Morning Trade - apnakal

May 06, 2025
pulisher
May 06, 2025

$5M Public Offering: Pasithea Therapeutics Advances MEK Inhibitor Drug for Rare Disease Treatment - Stock Titan

May 06, 2025
pulisher
May 06, 2025

Pasithea Therapeutics Drug Shows Tumor Reduction In Pancreatic Cancer, Strong Early Trial Results - Benzinga

May 06, 2025
pulisher
May 06, 2025

Pre-market Movers: KTTA, SXTC, GLMD, TCMD... - RTTNews

May 06, 2025
pulisher
May 06, 2025

Pasithea reports promising data on cancer drug PAS-004 - Investing.com

May 06, 2025
pulisher
May 06, 2025

Pasithea reports promising data on cancer drug PAS-004 By Investing.com - Investing.com South Africa

May 06, 2025
pulisher
May 06, 2025

Pasithea Therapeutics Reports Promising Phase 1 Trial Results for PAS-004, Demonstrating Up to 91% pERK Inhibition and Tumor Volume Reduction in Advanced Cancer Patients - Nasdaq

May 06, 2025
pulisher
May 06, 2025

Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004 - GlobeNewswire

May 06, 2025
pulisher
May 06, 2025

Phase 1 Trial Reveals 91% Target Success: New Cancer Drug Shows Promise in Pancreatic Cancer Patient - Stock Titan

May 06, 2025
pulisher
May 01, 2025

Pasithea Therapeutics Files For Offering Up To 3.2 Mln Common Shares Together With Warrants, Says SEC Filing - marketscreener.com

May 01, 2025
pulisher
May 01, 2025

AMD Stock Signals Strong Buy Ahead of Earnings - The Globe and Mail

May 01, 2025
pulisher
Apr 29, 2025

Pasithea completes enrollment in cohort 6 of Phase 1 trial of PAS-004 - TipRanks

Apr 29, 2025
pulisher
Apr 29, 2025

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients - The Manila Times

Apr 29, 2025
pulisher
Apr 29, 2025

Pasithea's Cancer Drug Trial Hits Key Milestone: Latest Results from Advanced Treatment Study - Stock Titan

Apr 29, 2025
pulisher
Apr 24, 2025

Pasithea Therapeutics Announces Acceptance of Abstract for ASCO 2025 Presentation on PAS-004 Clinical Trial Data - Nasdaq

Apr 24, 2025
pulisher
Apr 24, 2025

Pasithea Therapeutics to Present Updated Data from Ongoing - GlobeNewswire

Apr 24, 2025
pulisher
Apr 24, 2025

New PAS-004 Cancer Trial Data Shows Clinical Activity and Safety Profile | KTTA Stock News - Stock Titan

Apr 24, 2025
pulisher
Apr 15, 2025

Pasithea Therapeutics (NASDAQ:KTTA) Shares Down 16.9% – Here’s What Happened - Defense World

Apr 15, 2025
pulisher
Apr 14, 2025

Pasithea Therapeutics Leads Healthcare Buzz Surge As Cancer Trial Clears Safety Hurdle, Moves To Next Dosing C - Asianet Newsable

Apr 14, 2025
pulisher
Apr 11, 2025

12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga

Apr 11, 2025
pulisher
Apr 11, 2025

Pasithea Therapeutics Leads Healthcare Buzz Surge As Cancer Trial Clears Safety Hurdle, Moves To Next Dosing Cohort - MSN

Apr 11, 2025
pulisher
Apr 10, 2025

12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga

Apr 10, 2025
pulisher
Apr 10, 2025

Pasithea Therapeutics progresses with cancer drug trial By Investing.com - Investing.com South Africa

Apr 10, 2025
pulisher
Apr 10, 2025

Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump - Benzinga

Apr 10, 2025
pulisher
Apr 10, 2025

Pasithea Therapeutics Gets Positive Safety Committee Recommendation for Advanced Cancer Drug Phase 1 Trial - marketscreener.com

Apr 10, 2025
pulisher
Apr 10, 2025

Dow Tumbles Over 800 Points; US Inflation Rate Falls In March - Benzinga

Apr 10, 2025
pulisher
Apr 10, 2025

KTTA’s Unexpected Surge: Analysis of Recent Performance - timothysykes.com

Apr 10, 2025
pulisher
Apr 10, 2025

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Apr 10, 2025
pulisher
Apr 10, 2025

Pasithea Therapeutics progresses with cancer drug trial - Investing.com

Apr 10, 2025
pulisher
Apr 10, 2025

Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation From Its Ongoing Phase 1 Clinical Trial Of Pas-004 In Advanced Cancer - MarketScreener

Apr 10, 2025
pulisher
Apr 10, 2025

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - GlobeNewswire

Apr 10, 2025
pulisher
Apr 10, 2025

Pasithea Therapeutics Corp. Announces Positive Safety Review Committee Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - marketscreener.com

Apr 10, 2025
pulisher
Apr 10, 2025

3 Reasons to Avoid HEES and 1 Stock to Buy Instead - The Globe and Mail

Apr 10, 2025
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Kapitalisierung:     |  Volumen (24h):